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ABSTRACT 
Objectives To explore patient experiences of living with, and receiving treatment for, PMR. 
Methods Semi-structured qualitative interviews, with 22 patients with PMR recruited from general 
practices in South Yorkshire. Thematic analysis using a constant comparative method, ran 
concurrently with the interviews and was used to derive a conceptual framework.  
Results 5 key themes emerged highlighting the importance of: 1) pain, stiffness and weakness, 2) 
disability, 3) treatment and disease course, 4) experience of care, 5) psychological impact of PMR.  
Patients emphasised the profound disability experienced that was often associated with fear and 
vulnerability, highlighting how this was often not recognised by health care professionals.  Patients ?
ĞǆƉĞƌŝĞŶĐĞƐĂůƐŽĐŚĂůůĞŶŐĞŵĞĚŝĐĂůĐŽŶǀĞŶƚŝŽŶ ?ƉĂƌƚŝĐƵůĂƌůǇĂƌŽƵŶĚƚŚĞĐŽŶĐĞƉƚŽĨ ‘ǁĞĂŬŶĞƐƐ ?ĂƐĂ
symptom, the use of morning stiffness as a measure of disease activity and the myth of full 
resolution of symptoms with steroid treatment.  Treatment decisions were complex, with patients 
balancing glucocorticoid side effects against persistent symptoms.  
Conclusions Patients often described their experience of PMR in terms of disability rather than 
focussing on localised symptoms.  The associated psychological impact was significant.   
Practice implications Recognising this is key to achieving shared understanding, reaching the correct 
diagnosis promptly, and formulating a patient-centred management plan.   
 
 
 
  
1. INTRODUCTION 
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic condition in people 
aged over 50 with an incidence of 1 in 1000 in this age group and a lifetime risk of 2.4% for women 
and 1.7% for men [1,2].  It is characterised by pain and stiffness in the hips and shoulders, raised 
inflammatory markers and response to glucocorticosteroids, although atypical presentations can 
occur in up to 20% of those affected [3,4].  PMR has a major impact on quality of life [5] and 
treatment with corticosteroids is associated with a high rate of adverse effects [6].  Despite this, it 
remains an under-researched and poorly understood condition with the lack of primary care 
research particularly notable considering that the majority of PMR is diagnosed and managed in 
primary care [7].  
Patients with PMR require frequent, comprehensive clinical assessments.  At each consultation 
assessment of disease activity and response to treatment is needed, as well as evaluation of 
treatment side effects and assessment for complications [8].  Exploring and understanding the 
patient experience of PMR as an  ‘illness ? is crucial in order to facilitate shared decisions about 
treatment, balancing symptom control and functional enablement against adverse effects of steroid 
therapy.  Much of the research into PMR to date however focusĞƐŽŶĂďŝŽŵĞĚŝĐĂůŵŽĚĞůŽĨ ‘ƚŚĞ
ĚŝƐĞĂƐĞ ?ĂŶĚcurrent clinical assessment therefore tends to be set in this paradigm.  
There is increasing emphasis in many areas of health care on patient reported outcome measures 
(PROMS) as one tool to help in the drive to achieve the goal of person-centred care.  Only by 
exploring patient experiences can the outcomes which are meaningful to patients be identified.  For 
example, in rheumatoid arthritis, an appreciation of the significance of fatigue was first identified 
through qualitative exploration [9,10] and it is now recommended that fatigue is measured in 
addition to the core outcome set in all clinical trials of the condition [11].  
There is work being done towards agreeing a core set of outcome measures for use in clinical trials 
of PMR [12].  However, there are no measures available which assess outcomes directly from the 
perspective of a patient with the condition.  A PROM developed specifically for PMR would 
contribute greatly to a comprehensive assessment of the condition.  The first step in developing a 
PROM is to determine the conceptual framework through qualitative studies of the target 
population [13].  
We therefore set out to explore patient experiences of living with, and receiving treatment for, PMR 
with the dual aims of enhancing understanding of the condition from the patient perspective and 
allowing derivation of a conceptual framework for future development of a PROM.  
 
2. METHODS 
Ethical approval for this study was obtained from the Dyfed Powys Research Ethics Committee (REC 
12/WA/0344, 15/11/12).  
Participants were recruited from 10 general practices from South Yorkshire.  A purposive sampling 
strategy was used to recruit practices which were diverse according to their Index of Multiple 
Deprivation score, list size and training status.   
Patients aged 50 years and over with a Read coded PMR diagnosis and classical PMR symptoms 
(documented in the electronic medical record as having bilateral shoulder and / or pelvic girdle pain 
and stiffness for at least 2 weeks, and evidence of an acute phase response (raised ESR / CRP)) were 
included.  
Patients with atypical features (e.g. normal ESR / CRP), were eligible if their diagnosis had been 
made by a rheumatologist.   Patients were excluded if they had significant dementia or memory 
impairment, a primary diagnosis of giant cell arteritis, a concomitant inflammatory arthropathy, 
active cancer or if the GP decided that participation ǁĂƐŶ ?ƚĂƉƉƌŽƉƌŝĂƚĞ (e.g. other terminal illness).   
An invitation letter and study information sheet were sent to suitable patients and if they wished to 
participate they replied directly to the research team.  Reminder letters were sent 2 weeks later to 
those that had not replied to the initial invitation.   
A topic guide (see appendix 1) was developed, informed by discussion with members of a PMR 
patient support group, a literature review and consultation with the study multidisciplinary advisory 
group.  Topics included in the initial guide were onset of the condition, symptoms and functional 
effects, diagnosis, flares and relapses, starting and stopping treatment, resolution of the condition 
and information provision.  An open questioning style was used with minimal prompts to allow 
themes to emerge naturally [14].  Interviews were conducted by either HT or CaM, in participants ? 
homes or in the Academic Unit of Primary Medical Care (University of Sheffield) according to 
participant preference.  After the ŝŶƚĞƌǀŝĞǁƐ ?ƉĂƚŝĞŶƚƐ ?ŶŽƚĞƐǁĞƌĞƌĞǀŝĞǁĞĚby HT to gather data on 
comorbidities, ESR / CRP results and steroid dose regimes. 
Interviews were taped, independently transcribed and then systematically analysed using a constant 
comparative method to establish themes grounded in the data [15].  NVivo10 software was used to 
manage the data.  Analytic codes and categories were developed through an iterative, thematic and 
self-conscious process, beginning in parallel with the data collection and informing subsequent 
interviews as concepts and themes emerged.  The process of constant comparison continued until 
theoretical saturation was reached and no new themes were emerging.  
Two researchers (HT and CaM) analysed the data independently and any differences were 
considered and discussed until agreement was reached.  A third researcher (NM) moderated a 
selection of interviews to ensure comprehensiveness and consistency of identified themes. 
10 practices took part in recruitment, with 7 of these identifying patients suitable for inclusion.  
Recruitment ranged from 0-7 patients per practice.   
43 patients were invited to participate.  There were 18 non-responders and 3 patients (all male) who 
ĂŐƌĞĞĚƚŽƚĂŬĞƉĂƌƚďƵƚǁĞƌĞŶ ?ƚƌĞƋƵŝƌĞĚĨŽƌŝŶƚĞƌǀŝĞǁĂƐĚĂƚĂƐĂƚƵƌĂƚion had been reached.  
12 men and 10 women were interviewed.  2 patients were excluded post-interview (one had his 
diagnosis revised to inflammatory arthritis during the course of his illness and one had extensive co-
morbidities and could not distinguish the effects of PMR from other conditions).  The age range of 
participants was 53-81 years and the range of time from diagnosis to interview was 5 months to 2 
years 3 months.  3 had been referred to secondary care at some stage in the course of their 
condition and the rest had been managed entirely in primary care.  (see appendix 2 for table of 
participant details).  
 
3. RESULTS 
5 key themes were identified which were all interlinked and related.  A conceptual framework was 
developed which reflected the relationship between the themes and subthemes (see appendix 3).  
 Theme 1: Pain, stiffness and weakness 
 ?/ĐŽƵůĚŚĂƌĚůǇŵŽǀĞŝŶďĞĚ, it was aching all down my back and I just felƚ ?/ƐƵĚĚĞŶůǇĨĞůƚ/ ?ĚĂŐĞĚ ?
like I were ĂďŽƵƚ ? ?ǇĞĂƌŽůĚ ?ƚŚĂƚ ?ƐǁŚĂƚŝt felt like.  And very stiff, very achy like when you turned 
ŽǀĞƌŝŶďĞĚŝƚǁĂƐƉĂŝŶĨƵů ? ?hWE ? ? 
There was significant heterogeneity in symptoms described by participants.  Some described severe 
pain whilst others described muscle ache, likened to that caused by flu or vigorous exercise.  In 
others, stiffness predominated and pain was mentioned secondarily to this.   
Although weakness is not a widely accepted symptom of PMR, and is not part of the recent 
classification criteria,[1] several patients used the term.  In most cases, with greater elaboration, it 
became clear that the term  ‘weakness ? was being used to describe limited function due to pain or 
stiffness.  However, a few participants were certain that they were experiencing true weakness.    
The majority of participants experienced variation in their symptoms through the day though there 
were a few who said that their pain and stiffness was constant.  Some did describe a classical 
morning stiffness pattern but most painted a more nuanced picture of diurnal variation with 
worsening of symptoms after periods of rest or after any significant activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theme 2: Disability  
 ?/ĐŽƵůĚŶ ?ƚƉƵƚŵǇ ĐŽĂƚŽŶ ?ĐŽƵůĚŶ ?ƚŐĞƚƵƉƚŚĞƐƚĂŝƌƐ ?ĐŽƵůĚŶ ?ƚŐĞƚŝŶĂŶĚŽƵƚŽĨƚŚĞĐĂƌĂŶĚ/ŶŽƚŝĐĞĚ- 
/ ?ǀĞŐŽƚĂŶĂůůŽƚŵĞŶƚĂŶĚ/ǁĞƌĞŝŶƚŚĞŐƌĞĞŶŚŽƵƐĞĂŶĚŽŶŵǇŬŶĞĞƐĂŶĚ/ĐŽƵůĚŶ ?ƚŐĞƚƵƉ ?/ ?ĚŐŽƚƚŽ
ĐƌĂǁůŽŶŵǇŬŶĞĞƐƚŽŐĞƚƐŽŵĞƚŚŝŶŐƚŽƉƵůůŵĞƵƉǁŝƚŚ ? ?hWE ? ? 
Many participants described profound disability which came on over a relatively short time period of 
time (typically days to weeks).  Often these were people who, despite their age, had previously been 
Box 1 ʹ Pain, stiffness and weakness 
  “ŶĚ/ƌĞĂůůǇƐĐƌĞĂŵĞĚŝŶƉĂŝŶ ?zŽƵŬŶŽǁ ?ƚŽŐĞƚĚƌĞƐƐ Ě ? Or even to lift my arms up.  The 
ƉĂŝŶǁĂƐƚĞƌƌŝďůĞ ? ?UPN 18 
 “tĞůůŝƚ ?ƐŶŽƚƉĂŝŶ ?ŝƚǁĞƌĞŵŽƌĞŽĨĂďĂĚĂĐŚĞĂŶĚ/ĐŽƵůĚŶ ?ƚĚŽŵƵĐŚ ?ǇŽƵŬŶŽǁ ? ?UPN 13 
 “ ? ?ƚŚĞƐŚŽƵůĚĞƌƐĂŶĚƚŚĞďŝĐĞƉƐ ? ? ?ƚŚĞǇĨĞůƚǀĞƌǇǁĞĂŬ ?ƚŚĞǇǁĞƌĞŶ ?ƚƉĂŝŶĨƵů ?ũƵƐƚǁŽƵůĚŶ ?ƚ
ǁŽƌŬ ?UPN 5 
 “tŚĞŶǇŽƵĨŝƌƐƚŚĂǀĞWDZ ?ŝƚƵƐĞĚƚŽƚĂŬĞŵĞƚŝůĂďŽƵƚƚĞĂ-time to actually come round.  And 
ĞǀĞŶǁŚĞŶ/ƐƚĂƌƚĞĚŽŶƚŚĞƉƌĞĚŶŝƐŽůŽŶĞ ?/ĚŝĚŶ ?ƚƐŽƌƚŽĨĐŽŵĞƌŽƵŶĚƐƚƌĂŝŐŚƚĂǁĂǇĂƐ/ ?ǀĞ
ƚŽůĚǇŽƵ ?ƵƚƚŚĂƚ ?ƐǁŚĞŶ/ŶŽƚŝĐĞĚƚŚĞƉƌĞĚŶŝƐŽůŽŶĞǁĂƐǁŽƌŬŝŶŐ ?ƚŚĂƚthe pain was -, I was 
ĨƌĞĞƌŵƵĐŚĞĂƌůŝĞƌŝŶƚŚĞĚĂǇ ? ?UPN 2 
 “/ǁŽƵůĚƐĂǇŵǇďĞƐƚƚŝŵĞŝƐ ? ?Ž ?ĐůŽĐŬǁŚŝůĞ ?ĂŶĚƚŚĞŶ/ƐĞĞŵƚŽŐĞƚƌĞĂůůǇƚŝƌĞĚ ?/ƚŚŝŶŬŝƚ ?Ɛ
ǁŚĞŶǇŽƵ ?ǀĞĚŽŶĞŵŽƐƚŽĨǁŚĂƚǇŽƵǁĂŶƚƚŽĚŽĂŶĚƚŚĞŶǇŽƵƐŝƚĚŽǁŶĂŶĚƚŚĞŶ/ŬŝŶĚŽĨ
ƐĞŝǌĞƵƉ ? ?UPN 3 
active and suddenly suffered a life-changing reduction in their ability to carry out many activities of 
daily living.  It was notable that participants often described their experience of PMR in terms of 
what the condition stopped them doing, rather than detailing specific symptoms.   
One repeated observation by patients was that they became so stiff that they ĐŽƵůĚŶ ?ƚƚƵƌŶŽǀĞƌŝŶ
bed.  A range of other activities were affected including getting dressed, toileting, managing stairs 
and getting in and out of a bath or the car. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theme 3: Experience of care 
 ?/ŵĞĂŶŝĨƚŚĞǇ ?ĚŚĂǀĞŐŝǀĞŶŵĞƐƚĞƌŽŝĚƐĨŽƌůŝŬĞ ? ? ? ? ?ŚŽƵƌƐĂŶĚŝƚŚĂĚƚŚĞĞĨĨĞĐƚŝƚĚŝĚ ?ƚŚĞǇǁŽƵůĚ
ŚĂǀĞŬŶŽǁŶůŽŶŐďĞĨŽƌĞ ? ?hWE ? 
The path to diagnosis was very variable.  Whilst some patients were diagnosed early on in the course 
of their illness, many felt that, with hindsight, a diagnosis could have been made earlier.  Some 
expressed significant frustration about this.  Several patients saw doctors multiple times and were 
tried on a range of treatments including analgesia, stopping statins, physiotherapy and in one case 
even antidepressants, prior to a diagnosis being made.   
Participants tended to feel that their condition was poorly understood by the medical profession.  
Many had been given patient information leaflets (PILS) and some found these useful in that they 
validated their experiences and gave them confidence.   Others however, were frustrated that the 
PILs portrayed the condition as mild and resolving within 2 years ǁŚĞŶƚŚŝƐǁĂƐŶ ?ƚƚŚĞŝƌĞǆƉĞƌŝĞnce.  
Patients and their relatives frequently sought information from the internet but despite this, were 
often left with a sense of uncertainty about PMR and its management.  
 
Box 2: Disability 
 “/ǁĞŶƚŽŶŚŽůŝĚĂǇŝŶƚŚĞ^ĞƉƚĞŵďĞƌĂŶĚŽŶƚŚĞŚŽůŝĚĂǇ ?/ƚŚŽƵŐŚƚŝƚǁĂƐƚŚĞƚƌĂǀĞůůŝŶŐƚŚĂƚŚĂĚ
done it, I couldn't turn over from front to back in bed.  And I couldn't get my hips down onto the 
loo.  I was fine then for a few more days and then still on that holiday, I had that same thing 
again.  I woke up and I was on my front, I couldn't get over in bed.  And I developed strange 
ƉĂŝŶƐĂĐƌŽƐƐƚŚĞƚŽƉŽĨŵǇƐŚŽƵůĚĞƌƐ ?/ĐĂŵĞďĂĐŬĨƌŽŵƚŚĂƚŚŽůŝĚĂǇ ? ?ĂŶĚ/ũƵƐƚǁĞŶƚĚŽǁŶ
within about a week of not being able to get out of bed, not being able to turn over in bed.  And 
ŵǇŚƵƐďĂŶĚǁĂƐĂĐƚƵĂůůǇƐǁŝŶŐŝŶŐŵǇůĞŐƐŽƵƚ ?ŐĞƚƚŝŶŐŵǇĂƌŵƐĂŶĚƉƵůůŝŶŐŵĞƵƉŽƵƚŽĨďĞĚ ? ?
UPN 2  
 “/ĚŝĚŶ ?ƚŬŶŽǁŚŽǁƚŽŐĞƚŝŶƚŚĞĐĂƌďĞĐĂƵƐĞŵǇůĞŐƐǁŽƵůĚŶ ?ƚďĞŶĚ ?ŵǇĂƌŵƐǁŽƵůĚŶ ?ƚďĞŶĚ ?ƐŚĞ 
ŚĂĚƚŽƉƵƚŽŶĞŽĨŚĞƌůŝƚƚůĞŽŶĞ ?ƐďŽŽƐƚĞƌƐĞĂƚƐŽŶƚŚĞĨƌŽŶƚƐĞĂƚƐŽ/ĚŝĚŶ ?ƚŚĂǀĞƚŽůŽǁĞƌŵǇƐĞůĨ
ƋƵŝƚĞƐŽůŽǁĂŶĚŝƚŚĂĚŐŽƚƚŽƚŚĞƐƚĂŐĞǁŚĞƌĞ/ĐŽƵůĚŶ ?ƚůŝĨƚŵǇĂƌŵƐƚŽĐŽŵďŵǇŚĂŝƌ ?ƌĞĂůůǇ
struggling with everything, walking upstairs and everything. ?UPN 14 
 “ ?ŝƚŐŽƚƚŽƐƵĐŚĂƐƚĂŐĞǁŚĞƌĞ/ǁĞƌĞůĂǇŝŶŐŝŶďĞĚĂŶĚƋƵŝƚĞĨƌĂŶŬůǇ/ĐŽƵůĚŚĂƌĚůǇŵŽǀĞŝŶďĞĚ
and at the top of my arms  W certainly from the elbow up to the top of the shoulder here and 
ŚĞƌĞ/ǁĂƐƐŽƌƚŽĨŐĞƚƚŝŶŐƚŚĞƐĞĐƌĂŵƉƚǇƉĞƉĂŝŶƐ ? ?UPN 21  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theme 4: Treatment and course of the condition 
 ?/ǁĂƐƐŵŝůŝŶŐĂŐĂŝŶďĞĐĂƵƐĞ/ ?ĚŐŽƚƚŚĞƉŽǁĞƌĂŶĚ/ ?ĚŐŽƚƚŚĞƐƚƌĞŶŐƚŚďĂĐŬ ?/ŐŽƚƚŚĞǁĂůŬŝŶŐďĂĐŬ ?/
ĐŽƵůĚŐŽŽƵƚ ? ?hWE ? 
Prednisolone treatment brought about rapid resolution of symptoms in the majority of patients and 
many reported being amazed and relieved at how quickly they were able to resume normal 
activities.  However, the burden of side effects from steroid treatment was also a strong theme.  
Weight gain, hyperactivity and irritability were the most frequently mentioned but there was a wide 
range of symptoms which patients attributed to the prednisolone.  For some patients it reached a 
point where they felt the side effects were worse than the symptoms of PMR itself, though others 
ǀŝĞǁĞĚƚŚĞƐŝĚĞĞĨĨĞĐƚƐĂƐ ‘ĂƐŵĂůůƉƌŝĐĞƚŽƉĂǇ ? ? Several patients also commented on the additional 
tablet burden associated with being on long term prednisolone treatment as most were also 
prescribed calcium and vitamin D supplements, a bisphosphonate and a proton pump inhibitor. 
Box 3: Experience of care 
 “ŶĚ/ǁĞŶƚƚŽƚŚĞĚŽĐƚŽƌƐ ?ǁĞůůƚŚĞǇǁĞƌĞƚĞůůŝŶŐŵĞƚŽƚĂŬĞƉĂƌĂĐĞƚĂŵŽůƐůŝŬĞĂŶĚƚŚĞŶƚŚĞǇǁĞƌĞ
ŶŽŐŽŽĚ ?ŚĞŝŶĐƌĞĂƐĞĚŝƚƚŽƐŽŵĞƐƚƌŽŶŐĞƌƐƚƵĨĨĂŶĚ/ǁĞŶƚďĂĐŬĂŐĂŝŶ ?/ƐĂŝĚ ‘ƚŚĞǇǁĞƌĞŶ ?ƚĚŽŝŶŐƵƐ
ĂŶǇŐŽŽĚ ?ĂŶĚƚŚĞŶ/ƐƵŐŐĞƐƚĞĚƚŽŚŝŵĐŽƵůĚŝƚďĞƚŚŝƐŝ^ŵǀĂƐƚĂƚŝŶƚŚĂƚ/ǁĞƌĞŽŶ ?ŶĚŚĞƐĂŝĚŚĞ ?Ě
ƚŚŽƵŐŚƚŽĨƚŚĂƚĂŶĚƐƚŽƉƉĞĚŝƚĨŽƌĂďŽƵƚĂŵŽŶƚŚ/ƚŚŝŶŬ ?ŶĚƚŚĂƚĚŝĚŶ ?ƚŚĂǀĞĂŶǇĞĨĨĞĐƚĂŶĚƐŽ/
went, I had a blood test and went for results of the blood test and he more or less knew what it were 
then straiŐŚƚĂǁĂǇ ? ?UPN 11  
 “/ƚŚŝŶŬ/ ?ĚďĞĞŶƵƉƚŽƐĞĞŚĞƌǁŚĞŶŝƚĨŝƌƐƚƐƚĂƌƚĞĚ ? ?ĐĂƵƐĞ/ĐŽƵůĚŚĂƌĚůǇǁĂůŬ ? ? ?  She kept sending me 
for these blood tests and the last time they wanted another blood test off me, my husband went up; 
ŚĞƐĂǇƐ ? ‘>ŽŽŬ ?ŵǇǁŝĨĞĐĂŶ ?ƚŐĞƚ ŽƵƚŽĨďĞĚƚŚŝƐŵŽƌŶŝŶŐ ? ?ŶĚƚŚĞǇƐĞŶƚĂĚŽĐƚŽr down to take it.  
And then he ƐĂǇƐƚŽŚĞƌ ? ‘/ƚŚŝŶŬǇŽƵŽƵŐŚƚƚŽƐĞŶĚŚĞƌŝŶŚŽƐƉŝƚĂů ?^ŚĞŶĞĞĚƐƚƌĞĂƚŝŶŐ ?^ŚĞ ?ƐŶŽƚ
ŐĞƚƚŝŶŐĂŶǇǁŚĞƌĞ ? ?ŶĚƚŚĂƚ ?ƐǁŚĂƚƐŚĞĚŝĚƚŚĞŶ ?ǇŽƵ see  W ƐŚĞƐĞŶƚŵĞƚŽŚŽƐƉŝƚĂů ? ?UPN 18 
 “I did actually have a month on a, what do they call it, you know the antidepressants, because I was 
going with all these pains and I wasn't getting anywhere at all.  But I knew as soon as I started on the 
antidep-, it wasn't for me and that was it, after the month I came off them and I thought well, you 
ŬŶŽǁ ?/ ?ŵũƵƐƚŐŽŝŶŐƚŽƐĞĞƚŚŝƐƚŚƌŽƵŐŚĂŶĚ/ ?ŵũƵƐƚŐŽŝŶŐƚŽŚĂǀĞƚŽƐĞĞǁŚĂƚ ?ƐŐŽŝŶŐƚŽŚĂƉƉĞŶ ?
ŶĚ/ ?ŵŐŽŝŶŐƚŽŚĂǀĞƚŽĐƌĞĂƚĞĞǀĞŶƚƵĂůůǇĂŶĚĂƐŬƚŽƐĞĞĂƐƉĞĐŝĂůŝƐƚŽƌƐŽŵĞƚŚŝŶŐ ?ďĞĐĂƵƐĞǁŚĞŶ
yŽƵŐĞƚƚŽŵǇĂŐĞĂŶĚǇŽƵ ?ǀĞďĞĞŶĨŝƚ ?ǇŽƵĚŽŬŶŽǁǇŽƵƌŽǁŶďŽĚǇ ?ǇŽƵŬŶŽǁŝĨƚŚĞƌĞ ?ƐƐŽŵĞƚŚŝŶŐ
ƌŝŐŚƚŽƌǁƌŽŶŐ ? “UPN 2 
  “tŚĞŶƚŚĞǇĨĞƚĐŚĞĚŵĞďĂĐŬŝŶĂŶĚƚŽůĚŵĞǁŚĂƚ/ ?ĚŐŽƚĂŶĚƐŚĞƉƌŝŶƚĞĚƐŽŵĂŶǇƐŚĞĞƚƐŽƵƚĂŶĚ
ƐŚĞƐĂŝĚ ?ƚŚĞĚŽĐƚŽƌ ? ‘ƚŚŝƐŝƐĞǆĂĐƚůǇǇŽƵ ? ĂŶĚŝƚǁĂƐ ?ƚŚĂƚǇŽƵĐĂŶ ?ƚŐĞƚŽƵƚŽĨďĞĚĂŶĚǇŽƵĐĂŶ ?ƚĚŽƚŚŝƐ
ĂŶĚǇŽƵĐĂŶ ?ƚĚŽƚŚĞŽƚŚĞƌ ? ?/ŵĞĂŶŝƚǁĂƐĂůůĂďŽƵƚŝƚĂŶĚŝƚǁĂƐŵĞ ?ĚĞĨŝŶŝƚĞůǇŵĞ ? ?UPN 17  
 “tŚĞŶƚŚĞǇƐĂŝĚǁŚĂƚ/ ?ĚŐŽƚ ?/ǁĂƐǀĞƌǇƉůĞĂƐĞĚǁŚĞŶƚŚĞǇŐĂǀĞŵĞƚŚĞŵĞĚŝĐĂƚŝŽŶĂŶĚŝƚƐƚĂƌƚĞĚto 
ǁŽƌŬƐŽǁĞůů ?/ǁĂƐǀĞƌǇŚĂƉƉǇĂďŽƵƚƚŚĂƚďƵƚǁŚĞŶƚŚĞǇƐĂŝĚƚŚĂƚƚŚĞƌĞ ?ƐŶŽĐƵƌĞĨŽƌŝƚďĞĐĂƵƐĞǁĞ
ĚŽŶ ?ƚŬŶŽǁǁŚĂƚŝƚŝƐ ?ƚŚĂƚǁĂƐĂďŝƚƵƉƐĞƚƚŝŶŐ ? ?UPN 5 
 “/ƚŚĞŶůŽŽŬĞĚŽŶůŝŶĞ ?dŚĞƌĞ ?ƐƋƵŝƚĞĂďŝƚŽŶůŝŶĞĂĐƚƵĂůůǇďƵƚŝƚĂůůƐĂǇƐƚŚĞƐĂŵĞƚŚŝŶŐ W they ĚŽŶ ?ƚ
know. ?UPN 6  
The rate and pattern of reduction of prednisolone dose varied considerably between participants, as 
did the degree to which patients took charge of this themselves versus being guided by their doctor.  
Many described being aware of a slight worsening in symptoms with each dose reduction but that 
this would settle after a few days.  Several patients had had more significant relapses at points 
during the disease course necessitating increasing their prednisolone dose.  In most cases this was 
experienced as a resurgence of their original symptoms though at a less severe intensity.   
Some of the participants were interviewed at a stage in their condition where they had reached very 
low doses of prednisolone or had even had a trial of stopping treatment altogether.  In some cases 
participants described balancing the negative effects of being on low dose prednisolone with the, by 
then mild, PMR symptoms to achieve their desired quality of life.  In general however there was a 
sense of not quite being back to the level of health that they had enjoyed prior to developing PMR.  
Some commented on the fact that they had aged during the disease course and become less fit due 
to reduced activity and the weight gain associated with treatment.  This combination of factors 
resulted in them not feeling that they were able to recover fully to their pre-morbid state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theme 5: Psychological impact 
 ?Ƶƚ ?ǁĞůů ?/ƚŚŽƵŐŚƚǁŽƌƐƚ ?ǇŽƵŬŶŽǁ ?/ƚŚŽƵŐŚƚ/ǁĞƌĞůŝŬ  ?ǁŚĂƚƚŚĞƐĞŝůůŶĞƐƐĞƐǁŚĞƌĞǇŽƵũƵƐƚĨŝŶŝƐŚ
ƉĂƌĂůǇƐĞĚ ?/ĚŽŶ ?ƚŬŶŽǁǁŚĂƚƚŚĞǇĐĂůůƚŚĞŵďƵƚ/ĨĞůƚŝƚǁĞƌĞŐŽŝŶŐƚŽďĞƐŽŵĞƚŚŝŶŐůŝŬĞƚŚĂƚ ?ďĞĐĂƵƐĞ
/ǁĞƌĞŐĞƚƚŝŶŐǁŽƌƐĞ ? ?hWE ? ? 
This was a striking and recurrent theme which linked closely with all of the other themes but 
particularly with that of disability ?dŚĞƉĂŝŶĂŶĚĚŝƐĂďŝůŝƚǇŝƚƐĞůĨĐůĞĂƌůǇŝŵƉĂĐƚĞĚŽŶƉĂƚŝĞŶƚƐ ?ŵŽŽĚ
but many also described feeling fearful about the possible diagnosis and prognosis.  Several patients 
Box 4: Treatment and course of the condition 
 “,e put me on these Prednisolone and it was like magic, it was just so good, you know, that I had no 
ƉĂŝŶĂŶĚ/ǁĞŶƚďĂĐŬĂŐĂŝŶƚŽůĞƚŚŝŵŬŶŽǁŚŽǁ/ǁĂƐŐŽŝŶŐŽŶĂŶĚ/ƐĂǇƐ ‘ƚŚĂŶŬǇŽƵ ?ǇŽƵŬŶŽǁ ?/ĐĂŶ ?ƚ
ƐĂǇƚŽǇŽƵǁŚĂƚĂĚŝĨĨĞƌĞŶĐĞƚŚĂƚ ?ƐŵĂĚĞƚŽŵĞ ? ?UPN 12 
 “/ũƵƐƚĚŝĚŶ ?ƚĨĞĞůůŝŬĞŵĞ ?ǇŽƵŬŶŽǁ ?ŝƚǁĂƐĂůŵŽƐƚ like somebody else was living inside. I became tense, 
sometimes, ŽƌĂďŝƚƌĂƚƚǇ ?ŶĚ/ƌĞĂůůǇĚŝĚŶ ?ƚůŝŬĞƚŚĞǁĞŝŐŚƚŐĂŝŶĂŶĚ/ƚŚŝŶŬ/ƉƵƚŽŶŽǀĞƌĂƐƚŽŶĞŝŶƚŚĞ
first few months, you know, I went up a whole size of clothing and everything, which was not nice 
really. ?UPN 19 
 “tĞůů/ĐĂŶƉƵƚƵƉǁŝƚŚŝƚ ?/ĐĂŶůŝǀĞǁŝƚŚŝƚ ?ŝƚ ?ƐĂĨĨĞĐƚĞĚŵĞĂůůƚŚĞƐĞĂĐŚĞƐĂŶĚƉĂŝŶƐ ?ĂĐŚŝŶŐĂŶĚƚŚĂƚ ?ŝƚ ?Ɛ
ŶŽƚĂƐŵƵĐŚŽĨĂƐŚĂƌƉƉĂŝŶ ?ŝƚ ?ƐũƵƐƚ ?ǇŽƵŬŶŽǁ ? like, nagging ache.  /ĐĂŶƉƵƚƵƉǁŝƚŚƚŚĂƚ ?ďƵƚŝƚ ?ƐũƵƐƚ ?/
think iƚ ?ƐƚŚĞƐĞƐŝĚĞĞĨĨĞĐƚƐǁŚĂƚ/ ?ŵŐĞƚƚŝŶŐ ǁŝƚŚƚŚĞƚĂďůĞƚƐǁŚĂƚ ?ƐǁŽƌƐĞ ?I feel as though this is worse 
now than the actual bad aching. ?UPN 13 
 “Yeah, I have put a bit of weight on with it and I've noticed that my stomach gets -, I never had a 
stomach but it gets really swollen, more so when I've had something to eat kind of thing and my face 
looks really bloated some days, you know, yeah, but I just think back to when I first started with it, you 
ŬŶŽǁ ?ĂŶĚ/ƚŚŝŶŬƚŽŵĞŝƚ ?ƐĂƐŵĂůůƉƌŝĐĞƚŽƉĂǇ ?ǇŽƵŬŶŽǁ ? ? UPN 14 
 “very time he dropped the dose for a week, I could tell that it had dropped dose and I weren't very 
well, but I carried on and it like worked itself off, I woƌŬĞĚƚŚƌŽƵŐŚŝƚƐŽƌƚŽĨƚŚŝŶŐ ?UPN 11 
specifically mentioned fearing that they had developed motor neurone disease, multiple sclerosis or 
some form of terminal muscle wasting illness.  Previously fit people suddenly felt vulnerable and lost 
confidence and independence.   
As a consequence there was frequently a significant sense of relief when a diagnosis of PMR was 
made.  The importance of having a label to validate their experience and symptoms was apparent 
and the relief was even greater because a diagnosis of PMR meant that they could immediately 
receive an effective treatment. 
After diagnosis, the focus of the psychological impact was different but it was still present.  Many 
then reported anxiety about disease trajectory and adverse effects of medication, as well as 
experiencing a sense of loss for the life they had prior to the condition developing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 5: Psychological impact 
 “ƚŽŶĞƚŝŵĞŚĞǁĂƐŝŶƚŚĞďĂƚŚƌŽŽŵĂŶĚŚĞ ?ĚďĞĞŶƚƌǇŝŶŐƚŽƉĞƌĨŽƌŵǁŝƚŚĂƚŽǁĞůĂŶĚĐŽƵůĚŶ ?ƚand he 
ƐƚĂƌƚĞĚĐƌǇŝŶŐĂŶĚŚĞďƌŽŬĞĚŽǁŶĂŶĚ/ǁĞŶƚƚŽŚŝŵĂŶĚ/ ?ǀĞŶĞǀĞƌŬŶŽǁŶŚŝŵĐƌǇůŝŬĞƚŚĂƚďĞĨŽƌĞĂŶĚ 
ŚĞƐĂǇƐ ‘/ ?ŵďůŽŽĚǇƵƐĞůĞƐƐ ? ? ? 
 “tĞůů ?/ƚŚŽƵŐŚƚŵĞůŝĨĞ ?/ǁŽƵůĚŶ ?ƚƐĂǇŵĞůŝĨĞŚĂĚĐŽŵĞƚŽĂŶĞŶĚďƵƚ/ǁĂs so  W  “ 
 “You thought your life, as it haĚďĞĞŶ ?ŚĂĚĨŝŶŝƐŚĞĚ ? ?UPN 1 and his wife 
  “EŽƚďĞŝŶŐĂďůĞ ?ĂƐ/ƐĂǇ ?ƚŚŽƐĞ ?ĚĂǇƐ/ĚŝĚŶ ?ƚƚĂŬĞĂŶǇ/ďƵƉƌŽĨĞŶďĞĨŽƌĞ/ƐĂǁƚŚĞĚŽĐƚŽƌ ?/ƌĞĂůůǇŚĂĚƚŽ
depend on my daughter, you know, yeah.  and frightened, really, being in the house on my own, like 
goinŐƵƉƐƚĂŝƌƐ ?ǇŽƵŬŶŽǁ ?ďĞĐĂƵƐĞĂůƚŚŽƵŐŚƚŚĞƌĞ ?ƐĂƌĂŝů ?ĂƐ/Ɛ Ǉ ?ŵǇůĞŐƐũƵƐƚǁŽƵůĚŶ ?ƚďĞŶĚƚŽŐŽƵƉ
ĂŶĚŽŶĐĞ/ŐŽƚƚŽƚŚĞƚŽƉŽĨƚŚĞƐƚĂŝƌƐǁŚĞŶƚŚĞƌĂŝůĨŝŶŝƐŚĞĚ ?/ĚŝĚŶ ?ƚŬŶŽǁŚŽǁ/ǁĞƌĞŐŽŝŶŐƚŽŐŽĂŶǇ
further, it were a real ordeal, you know, yeah.  AŶĚƚŚĞƌĞǁĞƌĞĐĞƌƚĂŝŶƚŚŝŶŐƐƚŚĂƚ/ĚĂƌĞŶ ?ƚƚŽǁŚĞŶ/
were on my own, I wouldn't have dared got in the bath, you know, unless somebody was in the house 
and I just kept the phone on me all the time, because I really thought I were going to fall at some poinƚ ? ?
UPN 14 
 “But as I say, it were just  W it got to a stage as I say when I went to the doctors  W it got to a stage when I 
were literally struggling to turn over in bed  W ƚŚĂƚǁĞƌĞƋƵŝƚĞĨƌŝŐŚƚĞŶŝŶŐďĞĐĂƵƐĞǇŽƵ ?ĚůĂǇŽŶǇŽƵƌďĂĐŬ
ĂŶĚĂůůŽĨĂƐƵĚĚĞŶǇŽƵ ?ƌĞ ƚŚŝŶŬŝŶŐ ‘ǁĞůů ?ŝƚ ?ƐĂůŵŽƐƚůŝŬĞďĞŝŶŐ ůŽĐŬĞĚŝŶǇŽƵƌďŽĚǇŝŶĂǁĂǇ ? ?Yeah  W you 
hear about  W and I forget what the name of these  W some of these things  W but these wasting away 
diseases  W I forget  W /ĐĂŶ ?ƚƌĞŵĞŵďĞƌǁŚĂƚƚŚĞŶĂŵĞŝƐ Wŝƚ ?ƐŽŶƚŚĞƚŝƉŽĨ my tongue now  W but you 
ƚŚŝŶŬ ‘ǁĞůů ?ŝĨŝƚ ?ƐƐŽŵĞƚŚŝŶŐƚŽĚŽǁŝƚŚƚŚĞŵƵƐĐůĞƐŽƌŝĨŝƚ ?ƐƐŽŵĞƚŚŝŶŐůŝŬĞƚŚĂƚŚĂǀĞ/ŐŽƚƐŽŵĞƚŚŝŶŐůŝŬĞ
ŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐĐŽŵŝŶŐŽŶŽƌƐŽŵĞƚŚŝŶŐůŝŬĞƚŚĂƚ ?ĂŶĚŶŽƚďĞŝŶŐĂĚŽĐƚŽƌ/ǁŽƵůĚŶ ?ƚŬŶŽǁǁŚĂƚƚŚĞ
symptoms are.  It frightened me quite frankly and it knocked me off balance in a way because  W ƐŽŝƚ ?Ɛ
made me feel more vulnerable. ?UPN 21 
 “/ǁĂƐũƵƐƚŐůĂĚƚŽŐĞƚĂĚŝĂŐŶŽƐŝƐ ?ǇŽƵŬŶŽǁ ?ĂŶĚ/ǁĂƐĞƵƉŚŽƌŝĐ ?ǇŽƵǁŽŶ ?ƚďĞůŝĞǀĞƚŚŝƐ ?ƵƚƚŚĞĚĂǇ
ƚŚĞǇƚŽůĚŵĞ/ ?ĚŐŽƚWDZ ?/ǁĂƐĞƵƉŚŽƌŝĐ ?/ǁĂƐƉŝĐŬŝŶŐƚŚĞƉŚŽŶĞƵƉƚŽŵǇƐŝƐƚĞƌĂŶĚƐĂŝĚ ‘/ ?ǀĞŐŽƚĂŶ
ĂŶƐǁĞƌŶŽǁ ?/ ?ǀĞŐŽƚƚŚŝƐ ?ďĞĐĂƵƐĞƚŽŵĞ/ǁĞƌĞƚŚĞŶŐŽŝŶŐƚŽŐĞƚƚŚĞĐƵƌĞĂŶĚŐĞƚďĞƚƚĞƌ ? ?UPN 2 
 “ĞĐĂƵƐĞ/ŚĂĚŶ ?ƚŚĞĂƌĚŽĨŝƚĂƚĂůů ?/ƌĞĂůůǇĚŝĚƚŚŝŶŬŽŚ ƚŚĂŶŬ'ŽĚƐŽŵĞďŽĚǇ ?Ɛůŝstening to me. I thought 
I was imagining it. ?UPN 3  
4. DISCUSSION AND CONCLUSION 
4.1 Discussion 
dŚŝƐŝƐƚŚĞĨŝƌƐƚƋƵĂůŝƚĂƚŝǀĞƐƚƵĚǇƚŽĞǆƉůŽƌĞƚŚĞĞĨĨĞĐƚŽĨWDZŽŶƉĂƚŝĞŶƚƐ ?ůŝǀĞƐ.  Studies of other 
chronic rheumatological conditions have contributed to a wealth of models describing the effects of 
long term conditions on patients and their families e.g. ƵƌǇ ?Ɛ ‘ŚƌŽŶŝĐŝůůŶĞƐƐĂƐďŝŽŐƌĂƉŚŝĐĂů
ĚŝƐƌƵƉƚŝŽŶ ? [16] and tĞŝŶĞƌ ?Ɛ ‘^ƚƌĂƚĞŐŝĞƐĨŽƌƚŽůĞƌĂƚŝŶŐƵŶĐĞƌƚĂŝŶƚǇ ? ? ? ? ?, and many of the themes 
identified in this study correlate well with these existing models.  ŝƐĞŶďĞƌŐ ?ƐĐŽŶĐĞƉƚŽĨƚŚĞ
ĚŝƐƚŝŶĐƚŝŽŶďĞƚǁĞĞŶ ‘ĚŝƐĞĂƐĞƐ ? ?ǁŚŝĐŚĚŽĐƚŽƌƐĚŝĂŐŶŽƐĞĂŶĚƚƌĞĂƚ ?ĂŶĚ ‘ŝůůŶĞƐƐĞƐ ? ?ǁŚŝĐŚƉĂƚŝĞŶƚƐ ?
experience) [18] is also highly relevant to PMR.  Given that PMR is a heterogenous condition, affects 
older age groups (who will have a huge range of comorbidities, life experiences and coping 
strategies), causes pain and disability and is treated with medication capable of causing significant 
harm, ƚŚĞŝŵƉŽƌƚĂŶĐĞŽĨĂƐƐĞƐƐŝŶŐ ‘ŝůůŶĞƐƐ ?ƌĂƚŚĞƌƚŚĂŶĨŽĐƵƐƐŝŶŐŽŶ ‘ĚŝƐĞĂƐĞ ?ŝƐƉĂƌƚŝĐƵůĂƌůǇ
pronounced.  The risk otherwise is of significant under- or over-treatment with associated harms.  A 
patient reported outcome measure for PMR could significantly contribute to a holistic assessment, 
ĂĐƚŝŶŐĂƐĂďƌŝĚŐĞďĞƚǁĞĞŶ ‘ĚŝƐĞĂƐĞ ?ĂŶĚ ‘ŝůůŶĞƐƐ ?ĂŶĚƚŚƵƐ ďĞƚǁĞĞŶĚŽĐƚŽƌĂŶĚƉĂƚŝĞŶƚ ? 
The results from this study support previous findings of the heterogeneity of PMR which contributes 
to the complexity of diagnosis and assessment of disease activity [3,19].  The terminology used when 
discussing symptoms is important in achieving a shared understanding between doctor and patient 
and enabling a correct diagnosis.  Recognising therefore that patients may describe weakness as a 
feature of PMR is important, whether or not it is truly a separate construct from pain or stiffness. 
Morning stiffness is a characteristic feature of inflammatory musculoskeletal conditions and is part 
of the diagnostic criteria for PMR.  However, there have been questions raised over the usefulness of 
this concept in this condition [12,20] and the findings from this patient group echo the suggestion 
that stiffness often persists through the day and is worse after any period of rest.  It may be more 
ĂƉƉƌŽƉƌŝĂƚĞƚŽĚŝƐĐƵƐƐƐƚŝĨĨŶĞƐƐƌĂƚŚĞƌƚŚĂŶ ‘ŵŽrnŝŶŐƐƚŝĨĨŶĞƐƐ ?ŝŶWDZ and the use of concepts such 
as duration of morning stiffness as outcome measures may be unhelpful.   
Participants in this study tended to describe the impact of PMR ŝŶƚĞƌŵƐŽĨ ‘ĚŝƐĂďŝůŝƚǇ ?ƌĂƚŚĞƌƚŚĂŶ
detailing localised symptoms.  Difficulty with carrying out a wide range of daily activities was 
described and this significantly affected quality of life.  Key limitations mentioned on many occasions 
were the inability to turn over in bed and the inability to get up after bending down.  These 
particular difficulties contributed to a sense of helplessness and vulnerability and exemplify the 
overlap between the themes of disability and the psychological impact of the condition.  The 
relatively rapid ĐŚĂŶŐĞŝŶƉĞŽƉůĞ ?ƐĂďŝůŝƚǇƚŽĐĂƌƌǇŽƵƚĞǀĞƌǇĚĂǇĂĐƚŝǀŝƚŝĞƐǁĂƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚ
disruption of normal roles,  ‘ůŽƐƐŽĨƐĞůĨ ?and a sense of uncertainty as has been described in studies 
of other long term conditions [16,17,21].  
Another striking emergent theme from these interviews was the profound psychological impact of 
the symptoms of PMR prior to diagnosis.  Many patients had significant anxiety about a wide range 
of potentially serious neurological and malignant conditions.  In cases where there was a perceived 
delay in diagnosis, this anxiety was exacerbated.  The symptoms of PMR have a wide differential 
diagnosis and controversy still exists as to the defining characteristics of the condition [19].  The 
diagnosis is often made over a series of consultations forming a process which may include an initial 
trial of treatment [8].  Understanding and acknowledging patient anxiety and addressing their 
specific fears during this process could improve patient experience.   
 
4.2 Strengths and limitations 
This study is unusual in that it recruited patients from primary care, the setting where the majority 
of patients with PMR are managed [7]. This is a true strength of this study and allows a wider 
transferability of the findings.  WŚŝůƐƚƉĂƚŝĞŶƚƐŵĂǇŶŽƚŚĂǀĞƌĞĐĞŝǀĞĚĂ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ĚŝĂŐŶŽƐŝƐ
from a rheumatology specialist, we only included those with a PMR diagnosis and evidence of 
meeting the classification criteria [3] for PMR  W namely bilateral pain and stiffness in the hips and 
shoulders and elevated inflammatory markers.  It was surprising that more men than women were 
recruited given that the quoted incidence ratio is 2:1 female to male [1] but, whilst we acknowledge 
that there are gender differences in the way patients experience chronic illnesses eg. in stress and 
ƌĞůĂƚŝŽŶƐŚŝƉƐ ?ǁĞĚŽŶ ?ƚďĞůŝĞǀĞƚŚĂƚƚŚŝƐƉĂƚƚĞƌŶŽĨƌĞĐƌƵŝƚŵĞŶƚĚĞƚƌĂĐƚƐĨƌŽŵƚŚĞƚƌĂŶƐĨĞƌĂďŝůŝƚǇŽĨ
the main findings.  
Both of the researchers carrying out the interviews and analysis in this study were GPs.  Their prior 
understanding of the condition therefore arose from this background and will no doubt have shaped 
the research process to some degree.  However, as researchers they also had training in qualitative 
interviewing and reflexive analytical skills and were systematic and self-conscious in their approach.  
The participants were aware of the researchers ? profession and this may have affected the way they 
discussed their experiences.  However the setting of the interviews and naturalistic style (as opposed 
to general practice consultation in a surgery) will hopefully have mitigated this to some degree.  
 
4.3 Conclusions 
This qualitative primary care study has broadened our understanding of PMR and its effects on 
ƉĂƚŝĞŶƚƐ ?ůŝǀĞƐ ?dŚĞĚŝƐĐƵƐƐŝŽŶs around pain and stiffness and the course of the condition were 
anticipated, but the severity and impact of the disability, the associated fear and vulnerability and 
the often less than ideal experience of care were all surprisingly strong themes.  The systematic 
analytical approach used in this study allowed these themes to emerge and be tested through 
constant comparison, ensuring that the resulting concepts are truly grounded in the patient 
experience.   
 
4.4 Practice implications 
This study highlights several important aspects of patients ? experiences of PMR which may not 
necessarily be recognised or considered by health care professionals in our traditional understanding 
of the condition.  Through greater professional understanding of the ways in which the condition 
affects patients, patient care may be improved.  
In addition to the 5 main themes identified from the interview data we have derived an itemised list 
of functional activities that participants reported being limited by their PMR.  We plan to use this, 
set in the context of the conceptual framework developed from the rich interview data, to design a 
patient reported outcome measure specific to PMR.  It is hoped that this will have both research and 
clinical utility by contributing to a standardised assessment of the condition 
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